|
Average time (years)
|
Average # compounds
|
PhrMA member company investments ($bn)
| Drug discovery |
5 years
|
10,000
|
$11.0 billion
|
Pre-clinical
|
1.5
|
250
|
IND Submitted
|
|
|
|
Clinical Trials Phase I, II, III
|
6
|
5
|
14.1
|
NDA submitted
|
|
|
|
FDA Review
|
2
|
1
|
4.1
|
Large scale manufacturing/Phase IV
|
2
|
1
|
3.7
|
Source: PhRMA, 2005
Chart 1. Sales by all categories, drugs >$1 billion, 2003 and 2004
Source: Newman, 2005
B=biologicals; N = natural products without modification; ND = modified natural products; S= synthetic; S/NM= synthetic by natural product mimic; S*=natural product pharmacophore; S*/NM=natural product pharmacophore or mimic
Chart 2. New Chemical Entities 1981-2005
Source: Newman, 2005
BIOTECHNOLOGY INDUSTRY TABLES
Table 5.
Global biotechnology at a glance in 2004
|
|
Global
|
US
|
Europe
|
Canada
|
Asia-Pacific
| |
|
|
|
|
Revenues ($m)
|
54.613
|
42.740
|
7.729
|
2.091
|
2.052
|
R&D expense ($m)
|
20.888
|
15.701
|
4.151
|
782
|
253
|
Net loss ($m)
|
5.304
|
4.317
|
484
|
408
|
94
|
Number of employees
|
183.820
|
137.400
|
25.640
|
7.370
|
13.410
|
|
|
|
|
|
| Number of companies |
|
|
|
|
Public companies
|
641
|
330
|
98
|
82
|
131
|
Private companies
|
3.775
|
1.114
|
1.717
|
390
|
554
|
Public and private companies
|
4.416
|
1.444
|
1.815
|
472
|
685
|
Source: Ernst and Young, 2005
Table 6. World’s Top 10 Biotechnology Companies
Company
|
2002 sales (US $millions)
|
Amgen
|
5.523
|
Genentech
|
2.212
|
Amersham
|
2.305
|
Serono
|
1.546
|
Genzyme
|
1.329
|
Chiron
|
1.276
|
Biogen
|
1.148
|
MedImmune
|
848
|
Invitrogen
|
649
|
Cephalon
|
507
|
Source: ETC Group, 2003
Share with your friends: |